Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca earnings per share forecasts raised by Barclays
10:52am, Wednesday, 12'th Apr 2023
AstraZeneca PLC (LSE:AZN) saw its full-year earnings per share forecasts raised by Barclays analysts, despite hints that upcoming trial updates were “dominating the narrative”. Dubbing the FTSE 10
AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
02:34pm, Tuesday, 11'th Apr 2023
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
AstraZeneca releases US$0.7bn after simplifying US RSV deal
02:41am, Tuesday, 11'th Apr 2023
AstraZeneca PLC (LSE:AZN), Swedish Orphan Biovitrum AB (Sobi) and Sanofi have updated and simplified their agreements relating to the development and commercialisation of nirsevimab in the US. As a re
2 Top Biotech Stocks to Buy Right Now
05:20am, Friday, 07'th Apr 2023
Pfizer and AstraZeneca each possess stacked product portfolios and pipelines. Pfizer is a dirt-cheap stock.
McDonald's, U.K. Pharma Giant Hit New Highs
02:38pm, Thursday, 06'th Apr 2023
Dow Jones component McDonald's hits new high ahead of earnings as shares trade in a buy zone. The post McDonald's, U.K. Pharma Giant Hit New Highs appeared first on Investor's Business Daily.
AstraZeneca premium justified by long-term potential says broker
07:20am, Thursday, 06'th Apr 2023
Encouraging Phase III DUO-O trial results from a new combination of AstraZeneca's Imfinzi and Lynparza drugs plus Avastin in advanced ovarian cancer could give a boost to expectations for the UK pharm
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
01:42pm, Wednesday, 05'th Apr 2023
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer
10:20am, Wednesday, 05'th Apr 2023
AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge. The post Medical Behemoth AstraZeneca Flirts With Breakout On Fresh
AstraZeneca drug combo improves ovarian cancer survival rate
03:07am, Wednesday, 05'th Apr 2023
AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, has announced encouraging results from a planned interim analysis of its DUO-O phase III trial. The study assessed the combination o
Harbor Capital Appreciation Fund Buys AstraZeneca, Ups Nvidia Holding
04:24pm, Monday, 03'rd Apr 2023
The Harbor Capital Appreciation Fund (Trades, Portfolio) disclosed its equity portfolio for the first quarter of 2023 last week.
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
01:41pm, Monday, 03'rd Apr 2023
CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
7 Growth Stocks That Pay Generous Dividends
08:43am, Thursday, 30'th Mar 2023
When it comes to dividend-paying growth stocks, it can be difficult to find names that are both high-growth and high-yield. This makes sense, given that companies with high dividend yields are typical
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
03:42pm, Monday, 27'th Mar 2023 Zacks Investment Research
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
06:29pm, Friday, 24'th Mar 2023 Zacks Investment Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
10:15pm, Thursday, 23'rd Mar 2023 Zacks Investment Research
Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.
